User:EleanorBrumby/sandbox

= Professor Alan Boyd = Professor Alan Keith Boyd BSc (Hons) MB ChB FRSB FFLM FRCP FFPM FMedSci (born 16 November 1954) is the Past-President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, CEO and founder of Boyd Consultants Ltd and a Pharmaceutical Physician. Professor Boyd has made leading contributions to developing medicines in industry, facilitated numerous drug development programmes with academics, and driven the recognition for the new specialty of Pharmaceutical Medicine.

His industry work developed multiple products that are now approved medicines for a wide range of indications. He is globally recognised as a pioneer in gene-based therapies, having led the development of the first gene therapy to be submitted for regulatory approval and being involved in nine of the ATMP s that are now approved medicines. As a Fellow of the Faculty of Pharmaceutical Medicine he played a key role in establishing a postgraduate speciality programme which has supported GMC accreditation of 400 post-graduate trainees receiving a CCT in the specialty.

Early life and education
Alan attended Blackpool Collegiate Grammar School (1966 - 1973) and went on to the University of Birmingham from the years 1974 - 1980 in which he became a graduate in Biochemistry and Medicine.

Pharmaceutical Industry Career
Professor Boyd began his pharmaceutical industry career in 1984 where he worked for Glaxo Group Research Limited (1984 - 1986) as a clinical pharmacologist, focusing on the earlier stages of drug development. From 1988 he led ICI Pharma's cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada. In 1995 Alan became the Global Head of Medical Research for Zeneca Pharmaceuticals and was responsible for the global medical development of all their products.

After four years as Global Head of Medical Research at Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular, he led the development of their gene therapy based medicines portfolio.

Ark Therapeutics grew into an established healthcare company with five products in the company’s portfolio, the lead product being Cerepro®, for Malignant Glioma. Alan led the development of these gene-based therapies and it is of note that Cerepro® was the first gene therapy to be submitted to the European Medicines Agency for approval as a prescription medicine. Although it did not subsequently receive regulatory approval, the Marketing Authorisation Application filing of Cerepro® and its review by the EMA , paved the way for the other cell and gene-based therapies that followed it and helped set the future standards as required by the various Regulatory Agencies worldwide.

In April 2005, he left to set up Boyd Consultants, the focus of which is to aid and support early-stage life-science based companies and academic groups develop their research ideas into potential medicines. His clients now include many companies in Europe, North America and Japan who are devoted to the development of medical drug products, devices and in vitro devices.

A graduate in Biochemistry and Medicine from the University of Birmingham, UK, Professor Boyd is also a Fellow and Past-President of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He was previously Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at The Royal College of Physicians, United Kingdom.

In November 2009 he was appointed an Honorary Professor at the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development.

Association Memberships

 * Member of the British Medical Association
 * Member of the British Association of Pharmaceutical Physicians (BrAPP)
 * Fellow of the Royal Society of Medicine
 * Member of the British Pharmacological Society

Fellowships and Awards

 * 2009: Appointed Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School
 * 2014: Fellow of the Royal Society of Biology
 * 2015: President of the Faculty of Pharmaceutical Medicine
 * 2015: Council Member of the Royal College of Physicians of London
 * 2015: Council Member of the Academy of Medical Royal Colleges and an elected Board Trustee
 * 2016: ‘Outstanding Contribution Award’ at the 15th Annual UK Bionow Awards
 * 2018: Fellow of the Royal College of Physicians, London
 * 2018: Queen's Award for Enterprise awarded to Boyd Consultants
 * 2019: Independent Clinician Trustee to the Board of Trustees at the Academy of Medical Royal Colleges
 * 2019: Honorary Fellow of the Faculty of Forensic and Legal Medicine, Royal Colleges of Physicians
 * 2019: Business of the Year by South Cheshire Chamber awarded to Boyd Consultants
 * 2019: Dudley Buxton Prize by the Royal College of Anaesthetists
 * 2021: Fellowship at the Academy of Medical Sciences
 * 2022: Cheshire Life and Living Edge Platinum Jubilee 70 Cheshire Champions
 * 2022: FPM President's Medal by the Faculty of Pharmaceutical Medicine

Publications

 * Boorjian S, Alemozaffar M, Konety B, …. Boyd A,…et al. 2020. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle invasive bladder cancer. The Lancet Oncology, 22:1
 * Boyd A. 2020. Commentary on "Regulatory Science and Innovation Programme for Europe (ReScIPE): a proposed model". Br J Clin Pharm 2021;1–2
 * Stonier P, Silva H, Boyd A, et al 2020. Evolution of the Development of Core Competencies in Pharmaceutical Medicine and Their Potential Use in Education and Training. Frontiers in Pharmacology,11:1.
 * Morris T, Brostoff J, Stonier P & Boyd A. 2020. Evolution of Ethical Principles in the Practice of Pharmaceutical Medicine from a UK Perspective. Frontiers in Pharmacology, 10:1525
 * Boyd A, Cottam B, Obiora K, et al. 2017. The Faculty of Pharmaceutical Medicine – Foundation, function and future. Journal of Medicines Development Sciences, 3: 193.
 * Shore N, Boorjian S, Canter D, … Boyd A... et al. 2017.Intravesical rAd-IFNα/Syn3 for Patients with High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Clin Oncol, 35:3410
 * Webster S, McBride A, Binnie M, …..., Boyd A, et al. 2017. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343: Clinical evaluation of 11β-HSD1 inhibitor UE2343. Br J Pharmacology, 174:396
 * Webster S, McBride A, Binnie M, …..., Boyd A, et al. 2017. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343: Clinical evaluation of 11β-HSD1 inhibitor UE2343. Br J Pharmacology, 174:396